Medical Marijuana Legalization News

On Tuesday, lawmakers in New York approved a bill legalizing recreational marijuana for adults 21 and older. The bill was also signed into law by Gov. Andrew Cuomo on Tuesday, meaning it’s now legal for consumers in the state to possess and use it. 

Under the bill, New Yorkers aged 21 and older can now legally: 

• Possess up to three ounces of cannabis for recreational use; 

• Possess up to 24 grams of concentrated cannabis, such as oils derived from a cannabis plant; 

• Use, smoke, ingest, or consume cannabis products; 

• Give cannabis products to others who are 21 and older; and 

• Store up to five pounds of cannabis at home as long as they take “reasonable steps” to ensure that it’s stored in a secure place. 

The law makes it legal for consumers in the state to smoke marijuana anywhere it’s legal to smoke tobacco; it is not permitted in workplaces, schools, or inside a car. Smoking publicly in any of those areas could result in a civil penalty of $25 or up to 20 hours of community service.

Impaired driving still illegal 

In the bill, lawmakers clearly state that it remains illegal to drive under the influence of marijuana. Police will be able to pull people over if they suspect they are driving under the influence of marijuana and will be able to use the smell of cannabis to back up their suspicion. 

Police won’t, however, be allowed to search parts of the vehicle that aren’t accessible to the driver. For example, an officer wouldn’t be allowed to search the trunk for marijuana.  

Since there’s currently no tool to tell whether a person is under the influence of cannabis, the new law instructs the Health Department to look into potential devices that could detect whether a driver is high through a saliva sample. 

Retail licenses

As far as retail sales go, the law opens the door for dispensaries to let people purchase products. Officials must still set certain regulations -- for example, rules determining how the industry will operate, how sales will be taxed, and how licencing will work for cultivators and others in the industry. The first sales are expected sometime in 2022. 

New Yorkers will also soon be able to get cannabis delivered to their homes since the law makes it legal to establish cannabis delivery businesses. 

A new report published by researchers from Washington State University is encouraging health care providers to get candid with their patients about cannabis use. According to the researchers, being open and honest about this can only help patients receive the best medical care. 

“We want providers to ask people about their cannabis use and we want patients to feel comfortable talking about it, but right now many don’t,” said researcher Marian Wilson. 

Patients opening up about their needs

Recently, more and more consumers have been using cannabis to help treat a variety of medical issues, including chronic pain and illness and mental health concerns. By creating an open dialogue between health care providers and patients, medical professionals can better tailor their recommendations to their patients’ needs. The researchers say cannabis use could be an integral part of that. 

“Central to patient-centered conversations is understanding the top priorities of patients,” said Wilson. “Researchers have suggested that clinicians should ask ‘What matters to you?’ as well as ‘What is the matter?’” 

A recent study found that these types of conversations are happening more frequently between health care providers and their patients -- particularly with older adults. Cannabis use is on the rise among the older demographic, as it has been beneficial in treating everything from insomnia to chronic pain. 

Widespread use

Despite this progress, Wilson explained that the stigma associated with cannabis can be a roadblock for patients to be totally honest with their doctors. However, marijuana legalization -- for both recreational and medical use -- in the 2018 and 2020 elections is expected to ease some patients’ discomfort or uncertainty in broaching the topic with their health care providers. 

The popularity of CBD products has also helped ease some of the worries patients have about divulging their cannabis use. Consumers can find CBD products in popular stores like Walgreens and Dollar General, and products like drinks and snacks can discreetly provide the necessary benefits. 

While patients need to feel that they can trust their doctors to have these kinds of conversations, Wilson also explained that doctors need to be armed with the necessary medical information to help guide their patients in the best way. Moving forward, she’s hoping that experts create a resource that could be referenced in doctor-patient interactions and ensure that patients are getting the most accurate, beneficial information about cannabis use. 

“We want this paper to guide providers in how they can start opening up this conversation and normalizing it,” Wilson said. 

As more and more states legalize marijuana, consumers are reaping the medical benefits of cannabis-based products. 

Now, a new study conducted by researchers from the University of California at San Diego has found that older adults are really taking advantage of these products -- particularly for medical purposes. Their work revealed that consumers over the age of 60 have started using cannabis for a wide variety of conditions, including chronic pain and sleeping troubles. 

“Surprisingly, we found that nearly three-fifths of cannabis users reported using cannabis for the first time as older adults,” said researcher Kevin Yang. “These individuals were a unique group compared to those who used cannabis in the past.” 

A new wave of cannabis users

The researchers surveyed nearly 570 participants over the age of 65 to understand how often they were using cannabis products and the reasons they preferred them. The survey revealed that more than half of the participants used cannabis-based products on a regular basis for medical purposes, though more than 60 percent hadn’t started using cannabis until they were over the age of 60. 

“Pain, insomnia, and anxiety were the most common reasons for cannabis use and, for the most part, patients reported that cannabis was helping to address these issues, especially with insomnia and pain,” said researcher Christopher Kaufmann, PhD. 

According to the researchers, there are several reasons why cannabis use has become so widespread among older adults. For starters, CBD products are made without THC, which is the active ingredient in marijuana. This makes them more approachable to some consumers since they can use products like lotions or oils and get pain or anxiety relief without any of the added side effects. Additionally, the large variety of these kinds of products makes them easier than ever to access. 

“New users were more likely to use cannabis for medical reasons than for recreation,” said Yang. “The route of cannabis use also differed with new users likely to use it topically as lotion rather than by smoking or ingesting edibles. Also, they were more likely to inform their doctor about their cannabis use, which reflects that cannabis use is no longer stigmatized as it was previously.” 

Better outcomes reported

Though the survey participants reported better physical and mental health outcomes with the use of cannabis, the researchers want to do more work in this area to better understand the best ways that this plant-based approach can continue to benefit consumers. 

“There seems to be potential with cannabis, but we need more evidence-based research,” Dr. Kaufmann said. “We want to find out how cannabis compares to current medications available. Could cannabis be a safer alternative to treatments, such as opioids and benzodiazepines? Could cannabis help reduce the simultaneous use of multiple medications in older persons? We want to find out which conditions cannabis is most effective in treating. Only then can we better counsel adults on cannabis use.” 

The Transportation Security Administration (TSA) has updated its guidelines on flying with products containing hemp-derived CBD (or cannabidiol).  

The agency now allows fliers to place products and FDA-approved medications containing CBD in carry-on baggage and checked luggage. However, passengers still aren’t permitted to fly with marijuana.

“Possession of marijuana and certain cannabis infused products, including some Cannabidiol (CBD) oil, remain illegal under federal law,” the TSA warned. “TSA officers are required to report any suspected violations of law, including possession of marijuana and certain cannabis infused products.”

Farm Bill regulations

Prior to updating its rules, the TSA “made no distinction between marijuana and hemp-derived preparations,” according to Marijuana Moment, a marijuana policy and advocacy blog.

The agency’s new policy follows the introduction of the 2018 Farm Bill, which legalized hemp -- a non-psychoactive compound found in cannabis plants.

“Products/medications that contain hemp-derived CBD or are approved by the FDA are legal as long as it is produced within the regulations defined by the law under the Agriculture Improvement Act 2018,” the TSA said.

The TSA said it updated the language in its guidelines when it became aware of confusion regarding the status of Epidiolex, an FDA-approved epilepsy drug which contains CBD.

"To avoid confusion as to whether families can travel with this drug, TSA immediately updated TSA.gov once we became aware of the issue," a TSA spokesperson told CNN.

Though just 20 percent of states have legalized marijuana for recreational purposes, many legislators nationwide have given the green light for health care professionals to use the drug for medicinal purposes.

Now, health care experts are bringing up some cause for concern when it comes to prescribing cannabis to patients.

“Consistently across medicine, pharmacy, and nursing, health professionals all said their knowledge of medical cannabis was poor,” said researcher Kyle Gardiner. “Many highlighted a need for further education and easy-to-access information. Where they felt evidence-based resources were not accessible, their knowledge was generated from online learning, news and media, and patient experiences.”

What the experts are saying

The researchers analyzed nearly 30 previous studies that have assessed health care professionals’ beliefs and attitudes regarding medical cannabis use.

The studies included responses from pharmacists, allied health professionals, nurses, and medical practitioners, the majority of whom agreed that medical cannabis should be used; however, the respondents said they needed better information to properly guide their patients.

“It is important to know [medical professionals’] attitudes and concerns about the delivery and use of medical cannabis, what knowledge they have, and where they are getting their information,” Gardiner said. “However, these are a few pieces of a much larger picture.”

Gardiner notes that patients are only granted access to medical cannabis if they are properly prescribed it by a health care professional, further proving how vital their role is in these cases.

While many of the health care experts involved in this study expressed their own ignorance about the issue -- including the proper dosage to give to patients, where the drug is legal, and where they can get it -- they also shared that they were concerned for their patients’ overall well-being.

The health care experts had patients’ mental health at the forefront of their minds, as previous studies have revealed a relationship between medical cannabis use and overall mental health, while drug misuse, driving under the influence, and interactions with other drugs were other big concerns around prescribing medical cannabis.

Moving forward, Gardiner and his team want to ensure that patients are getting the highest quality of care that they possibly can, and this starts with understanding where health care professionals come from in their decision-making.

“The picture we need to build is a more robust understanding of health professional behaviour,” said Gardiner. “This is an important step in recognising and better informing strategies that change the way health care is delivered so that patients are not disadvantaged. This study is one part of putting together that picture relating to medical cannabis.”

Understanding marijuana use

Medical marijuana has been touted to help any number of conditions, but a recent study found that adults with cancer are more likely to use the drug to manage their pain than those without cancer.

The study spanned from 2005 through 2014, and though marijuana use among adults rose across the board, cancer patients were more likely to manage the pain with marijuana than their counterparts.

“Medical marijuana legalization has been previously associated with a reduction in hospitalizations related to opioid dependence or abuse, suggesting that if patients are in fact substituting marijuana for opioids, this may introduce an opportunity for reducing opioid-related morbidity and mortality,” said Dr. Jona Hattangandi-Gluth. “Of course, it will also be important to identify risks and adverse effects of marijuana, which has not previously been studied on large randomized clinical trials, given its scheduling as a class 1 controlled substance.”

On Thursday, The Food and Drug Administration (FDA) published a press release in which it said it’s currently looking for “pathways” to legalize the sale of CBD oil and other cannabis-derived compounds in food and beverages.

The press release was put out just after President Trump signed the 2018 Farm bill into law. The bill legalized industrial hemp by removing it from the Controlled Substances Act, but it didn’t strip the FDA of its power to regulate products containing cannabis.

“In view of the proliferation of products containing cannabis or cannabis-derived substances, the FDA will advance new steps to better define our public health obligations in this area,” FDA Commissioner Scott Gottlieb said. “We’ll also continue to closely scrutinize products that could pose risks to consumers.”

Growing consumer interest

Gottlieb stressed that because components of marijuana, such as THC and CBD, are “active ingredients in FDA-approved drugs” such as the recently approved epilepsy medication Epidiolex, it remains illegal to “introduce drug ingredients like these into the food supply, or to market them as dietary supplements.”

But the FDA said it’s “aware of the growing public interest in cannabis and cannabis-derived products.” The federal agency plans to hold a public meeting in the near future to collect input on how to legalize the marketing for cannabis-derived compounds.

“While products containing cannabis and cannabis-derived compounds remain subject to the FDA’s authorities and requirements, there are pathways available for those who seek to lawfully introduce these products into interstate commerce,” Gottlieb said. “The FDA will continue to take steps to make the pathways for the lawful marketing of these products more efficient.”

Loosening its stance

Currently, the FDA bars companies from adding CBD and THC to food, drinks, and supplements. It also prohibits companies from making any therapeutic claims about their products if these ingredients are included.

However, the agency said it recognizes the “potential opportunities that cannabis or cannabis-derived compounds could offer and acknowledge the significant interest in these possibilities.”

“We’re committed to pursuing an efficient regulatory framework for allowing product developers that meet the requirements under our authorities to lawfully market these types of products,” Gottlieb said.

Following its approval of Epidiolex earlier this year, the FDA stated that “CBD has a negligible abuse potential.” It’s a non-psychoactive compound with a growing body of anecdotal evidence that it helps with a range of conditions, such as anxiety, sleep disorders, and inflammation.

Although not currently permitted under federal law, companies have already started infusing products like coffee, cocktails, and cosmetic products with CBD.

Yesterday’s midterm elections showed once again that marijuana legalization is one of the few issues where Americans voting for Red or Blue largely agree.

In Missouri, 66 percent of voters came out in support of medical marijuana legalization despite opposition from nearly every major physicians’ group in the state.

Under Amendment 2, patients will need a doctor’s approval to possess medical marijuana. But once they obtain permission, patients or their registered caregivers will be able to grow up to six marijuana plants.

The amendment also calls for the creation of legal dispensaries where qualified patients can purchase up to four ounces of cannabis on a monthly basis.

Utah voters also supported a ballot proposal to legalize weed, and Utah medical marijuana advocates credit the issue as one of the major factors bringing people to the polls. Voters in the state approved Proposition 2 53-47 percent.

Rewriting the laws

That doesn’t mean residents will have immediate access to medical marijuana. Measures in both states are at the mercy of state lawmakers, who may try to rewrite the laws before they are implemented.  Arkansas was the first red state to legalize medical marijuana with a voter-approved state amendment back in 2016, but patients still can’t legally access cannabis. A state panel charged with distributing permits to dispensaries and patients has blamed a major backlog for slow implementation.

"We hope lawmakers will implement the measure efficiently and effectively to ensure qualified patients can gain access to their medicine as soon as possible," Matthew Schweich, deputy director of the national advocacy group Marijuana Policy Project, told the Kansas City Star in reference to the measure in Missouri.

Meanwhile, Michigan voters yesterday went a step further, voting 54-44 to legalize marijuana for recreational purposes. Opponents to the measure claim the fight isn’t over and say they plan to challenge the law in the courts. But advocates like the Coalition to Regulate Marijuana like Alcohol say that Michigan voters “have resoundingly confirmed their support for legalizing and regulating marijuana."

Cannabis companies who claim that their products shrink tumors or perform other miracles have never been very popular with the Food and Drug Administration (FDA), which often sends producers letters to warn them that they can’t make unproven health claims.

But in a move that suggests more leneincy than is typical of the federal government’s attitude toward marijuana, the FDA is declining a prohibitionist group’s request to include cannabis in the agency’s list of over-the-counter drugs that it says are not generally recognized as safe or effective.

Any drug manufacturer that makes the FDA’s list, officially called a “negative monograph,” is legally prohibited from marketing over-the-counter drugs without prior approval by the FDA. Drugs currently on the list include over-the-counter daytime sedatives and some herbal medicine, but cannabis appears to be safe from that negative distinction for now.

Request denied

Drug Watch International, a group that warns consumers about side effects caused by traditional pharmaceuticals but is also opposed to marijuana legalization, sent a petition to the FDA last year urging the agency to give cannabis a negative monograph.

Doing so could allow regulators to “immediately make such [health] claims unlawful and subject the sponsors to regulatory action, including injunctive seizure of mislabeled and misbranded drugs, as well as other potential sanctions,” the group said.

Such a proposal could also have had frightening consequences for people in the medical cannabis industry. While anecdotal stories suggesting that cannabis can help cure everything from opioid addiction to depression are widespread, federal limitations on studying marijuana make such claims extremely difficult to prove.

That can put companies marketing to people seeking cannabis as medicine in a difficult position as they try to advertise their products.

But in a recent decision, the FDA told Drug Watch International that it was denying its request to reclassify cannabis or launch a tougher crackdown on misleading labels. Forbes magazine is reporting that the agency sent a letter to Drug Watch International on Monday stating that such a measure would essentially be overkill.

Such enforcement is "not necessary for the protection of public health," Janet Woodcock, the director of FDA's Center for Drug Evaluation, reportedly told the group last week.

Not lifting scrutiny entirely

It’s not that the FDA plans to stop investigating cannabis companies and their marketing labels. Woodcock added in her letter that the FDA will continue to take “enforcement action against illegal marketing of unapproved” cannabis products, but that classifying cannabis as a dangerous substance simply isn’t necessary to do so.

In addition to targeting cannabis companies with bombastic health labels, the FDA is also sending warning letters to companies that advertise cannabis products as dietary supplements and who market their products online.

According to the FDA, selling cannabis products to consumers across the country is a violation of federal laws that prohibit “interstate commerce without prior approval from the FDA.”

New York City Mayor Bill de Blasio is reportedly asking police to stop arresting people for smoking marijuana in public following an announcement last week that the Manhattan District Attorney’s office will stop prosecuting marijuana possession and smoking cases in criminal court.

“The dual mission of the Manhattan DA's office is a safer New York and a more equal justice system," Manhattan District Attorney Cy Vance said last week in a statement explaining the policy change.

"The ongoing arrest and criminal prosecution of predominantly black and brown New Yorkers for smoking marijuana serves neither of these goals."

Police unhappy with decision

The DA was pointing to data showing that non-white New York City residents are far more likely to be arrested for marijuana possession or use in public than whites, despite using marijuana at the same amounts.

Current laws in Manhattan require people who are caught with marijuana in public to be arrested, fingerprinted, and later appear in court. Under de Blasio’s policy change, people caught with weed would still be ticketed and summoned to appear in court, but they would not be arrested.

Police are apparently unhappy with the policy changes. On May 18, the official Twitter account of a police union called the Sergeants Benevolent Association published a post complaining about wanting to arrest a man smoking marijuana, but no longer feeling comfortable doing so.

“Will the NYPD back me? NOT! So I just walked away,” the SBA posted.

Now @ Penn Station a man is on the steps as hundreds of people pass smoking marijuana. With over 20 years as a cop I wondered should I arrest him, what if he’s illegal, will I get in trouble if he resist, oh Community policing? Will the NYPD back me? NOT! So I just walked away. pic.twitter.com/B9Ty0tRpMG

— SBA (@SBANYPD) May 18, 2018

In the days of prohibition of marijuana for any use, those who partook of the weed claimed that the government was missing a big source of revenue.

Just tax legal marijuana the way they do cigarettes and the money would come pouring in, they said.

Now that recreational marijuana use has been legal for a couple of years in Colorado and Washington, marijuana advocates are saying "I told you so."

FinancialBuzz.com, a news website emphasizing coverage of the financial side of cannabis, points to economic statistics showing legalized marijuana in Colorado created about 18,000 jobs in 2015 while generating about $2.39 billion in economic activity for that state.

It cites another publication, Marijuana Business Daily, as estimating that cannabis-related firms employed as many as 150,000 full- and part-time workers last year. The economic impact will only get bigger, it says, as the four states that legalized recreational marijuana last November begin to implement the new laws.

Making inroads on Wall Street

In fact, legal marijuana is making inroads on Wall Street with at least five publicly traded companies.

ChineseInvestors.com, which trades over-the-counter (OTC), launched a new website last week specializing in medical marijuana. It's also expanding into hemp oil, which is legal in both the U.S. and China.

GW Pharmaceutical, which trades on NASDAQ, focuses on developing and bringing to market prescription medicines made from cannabis extracts. The company currently markets Sativex, a spray used for the treatment of spasticity due to multiple sclerosis.

Cara Therapeutics Inc., which trades on NASDAQ, is a biotech company that develops pain medication. These products alleviate pain by selectively targeting kappa opioid receptors.

Zynerba Pharmaceuticals, also trading on NASDAQ, produces transdermal synthetic cannabinoid treatments for patients with high unmet medical needs.

Insys Therapeutics, trading on NASDAQ, develops and markets pharmaceutical cannabinoids and works to address what it says is the clinical shortcomings of existing commercial products.

Feds still skeptical

While the legal marijuana genie appears to be out of the bottle, it remains to be seen what position a Trump administration Justice Department will take. The Obama administration was opposed to the legalization votes that took place during its tenure but did little to interfere with Colorado and Washington's implementation.

There are also continuing health concerns. Dr. Stefan Kertesz, an associate professor with the University of Alabama at Birmingham School of Medicine, has been studying the effects of long-term marijuana use. A year ago, he reported long-term marijuana use appeared to be significantly associated with worse verbal memory in middle age.

That's probably not good news for Baby Boomers, many of whom smoked pot during their college days and apparently have taken it up again now that it's legal in places.

In December, researchers reported Boomers were using marijuana more than any other generation, including Millennials. Between 2006 and 2013, they found a 71% increase in marijuana use among adults 50 years old and older. The rate drops considerably for adults 65 and older, who make up the leading edge of the Baby Boom generation.  

Substance abuse can be pervasive at all ages, but a recent study conducted by researchers at Penn State shows that marijuana use is rising amongst teenagers. At the same time, other controlled substances, such as alcohol and cigarettes, are either remaining stable or declining in use within the same age group.

The war against smoking has been raging on for years. Many anti-smoking campaigns have targeted teens in the hopes that stopping the habit before it starts is the best solution. “Our analysis shows that public health campaigns are working—fewer teens are smoking cigarettes,” said Stephanie Lanza, who is a professor of biobehavioral health and the scientific director of the Methodology Center at Penn State.

Marijuana trends rising

Unfortunately, Lanza and her team have discovered that teens are not simply stopping when it comes to smoking. They are just replacing cigarettes with marijuana.

The researchers collected data from surveys that were given to high school seniors over a 37-year period, from 1976 to 2013. Over 600,000 students were questioned about their use of alcohol, cigarettes, and marijuana. The study used data that was originally collected by the University of Michigan for their own long-term study.

The statistical findings showed that, as of 2013, nearly 19 percent of white teens smoked cigarettes and 22 percent used marijuana. These numbers shift slightly for black teens, where only 10 percent smoke cigarettes but nearly 25 percent used marijuana. The researchers also found that teens were more likely to use marijuana if they smoked or drank excessively, and vice versa.

When compared to alcohol, though, cigarettes and marijuana still lag behind in teen use. Although these numbers have decreased since the 1970s, alcohol consumption is still more widespread amongst white teens than cigarette or marijuana use. But if abuse trends continue in this manner, then marijuana will likely begin to challenge alcohol consumption as the number one substance that teens abuse.

Decisive shift

“What will this look like in a few years?” asked Lanza when looking at graphs that showed black teens’ use of marijuana and alcohol consumption. “All signs point to these two lines crossing within the next few years. This is a decisive shift.”

Lanza and her colleagues will continue to analyze their data to see what else can be learned from it. They hope to see if the legalization of marijuana in several U.S. states will impact their figures in any significant way. The full study has been published in the Journal of Adolescent Health. 

Now that marijuana is sort of legal in some cities and states, there's growing pressure on local regulators to make sure the stuff that's being sold is safe and that its potency is clearly indicated on the packaging.

Trying to stay ahead of the curve, the desert resort city of Palm Springs, California, next week begins testing the marijuana sold in local dispensaries, according to local media reports.

The tests will be conducted by SC Labs of Santa Cruz, Calif., which already tests about 8,000 samples per month for 200 dispensaries in California. 

“People who are taking any type of drug need to know the amount of active ingredients,” said Josh Wurzer, president of SC Labs, according to the Santa Cruz Sentinel. “When you take a (marijuana) brownie, let’s say you don’t know if there’s 10 milligrams or 100 milligrams in it. Your day or the next couple of days are ruined.”

Safety concerns

Palm Springs officials say they're concerned mainly with ensuring that the products sold by local dispensaries are safe.

“Right now, we’re just taking baby steps,” said Jay Thompson, Palm Springs chief of staff who’s coordinating the pilot program. “Hopefully, as we get down the line, we can develop standards, but right now we’re just doing it for patient safety and for patient information.”

There are no state regulations covering marijuana in California and the federal government still regards it as illegal so for the time being, it's up to cities to oversee the quality of the local weed. Wurzer testing is necessary if marijuana is to grow out of its current cottage-industry status.

“For everyone involved, it would just be easier if there were set rules,” he said, according to the Sentinel. “Vague rules allowed the industry to innovate and find itself. Now is the time that we know what we’re getting into and what we need for rules and regulation.”

The debate over the legalization of marijuana has continued to rage on as states begin to adopt more lenient legislation on the matter. Proponents point out that there are numerous economic and health benefits that come along with legalizing the drug, but there are bound to be negative consequences as well.

One study shows that the chances of young children swallowing, breathing in, or otherwise being exposed to marijuana has increased dramatically as policies shift in its favor.

The numbers that have been uncovered by the study are truly staggering. From 2006 to 2013, exposure to marijuana for children five years of age or younger has risen 147.5% across the U.S. This number is small potatoes when compared to states that legalized marijuana for medical purposes. In these states, the rate increased almost 610% in the same time period.

States that legalized marijuana from 2000 to 2013 have had child exposure rates increase steadily. There is roughly a 16% increase each year, and there is always a more dramatic jump in the year that marijuana was legalized in each state.

But it is not just states that legalize marijuana that have to worry. Even states that had not legalized marijuana by 2013 saw a rise of 63% in marijuana exposure in young children from 2000 to 2013.

But why exactly is this exposure to young children occurring? Henry Spiller, who co-authored the study and is the director of the Central Ohio Poison Center at Nationwide Children’s, explains why children may be attracted to the drug.

"The high percentage of ingestions may be related to the popularity of marijuana brownies, cookies and other foods," he says. "Very young children explore their environments by putting items in their mouths, and foods such as brownies and cookies are attractive."

Coma, seizures, other complications

Exposure to marijuana has produced a range of results when it comes to children. While most instances resulted in minor clinical effects, some children suffered from coma, decreased breathing, or seizures. These more serious conditions could be due to increased amounts of THC in marijuana food products.  

Gary Smith, who is the senior author of the study and the director of the Center for Injury Research and Policy at Nationwide Children’s, urges that states need to have child protection laws in place when it comes to marijuana. Although the total number of exposure cases is less than 2,000, he believes that the growing trend in states that have legalized marijuana is very telling.

"Any state considering marijuana legalization needs to include child protections in its laws from the very beginning," Dr. Smith said. "Child safety must be part of the discussion when a state is considering legalization of marijuana," he said.

Should be locked up

Other researchers endorse the idea that marijuana be treated like other chemicals and medicines in a household. If marijuana products are being kept in the house, they should be kept out of sight of children. If possible, they can be locked in a cabinet to ensure that they cannot be swallowed by mistake.

The full study was published in Clinical Pediatrics on June 8, 2015.

Advocates of legalizing marijuana have been saying for years that it's the safest recreational drug of all, and now a study suggests that that's actually an understatement.

Marijuana is even safer than everyone thought it was while alcohol is even more dangerous, according to the study, published in Scientific American.  

Looking at what it takes to ingest a lethal dose, the researchers found that alcohol was 114 times more dangerous than THC, the active ingredient in marijuana. 

The study compared the estimated lethal dose of a number of drugs to the estimated human intake. Using this approach, alcohol, nicotine, cocaine and heroin fell into the "high risk" category, with alcohol having by far the highest risk profile.

Legal in Alaska

This perhaps comes as good news in Alaska, where a ballot measure to legalize and regulate marijuana for adults takes effect tomorrow (Tuesday). Alaskans age 21 and older will legally be able to possess up to one ounce of marijuana and cultivate no more than six plants at home, though commercial sales will have to wait until regulations have been established.

Colorado, Oregon and Washington have also legalized marijuana, and medical marijuana is permitted in 23 states and Washington D.C.

“We anxiously await the same public safety improvements from Alaska that we have already seen in Colorado and Washington,” said Maj. Neill Franklin (Ret.), executive director of Law Enforcement Against Prohibition (LEAP). “Cops will spend more time going after dangerous criminals and protecting communities, and parents can rest assured that their local marijuana retailer is barred from selling to their children.”

Legalization efforts continue in Congress, where Representatives Jared Polis (D-Colo.) and Earl Blumenauer (D-Ore.) introduced separate bills to tax and regulate the sale of marijuana for adults at the federal level. The measure is seen as having little chance of winning passage in the Republican-controlled Congress.